SELLAS Life Sciences Gr analyst ratings
SELLAS Life Sciences Gr analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/28/2022 | 158.62% | Cantor Fitzgerald | $10 → $6 | Maintains | Overweight |
| 07/21/2021 | 675.86% | Cantor Fitzgerald | → $18 | Initiates Coverage On | → Overweight |
| 11/15/2019 | 417.24% | Maxim Group | → $12 | Upgrades | Hold → Buy |
| 04/08/2019 | 93.97% | Alliance Global Partners | → $4.5 | Initiates Coverage On | → Buy |
| 11/01/2018 | 460.34% | Oppenheimer | → $13 | Initiates Coverage On | → Outperform |
| 07/20/2018 | 115.52% | Maxim Group | $13 → $5 | Maintains | Buy |
| 04/02/2018 | 374.14% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 03/19/2018 | — | Maxim Group | Upgrades | Hold → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 06/28/2022 | 158.62% | 坎托·菲茨杰拉德 | 10 美元 → 6 美元 | 维护 | 超重 |
| 07/21/2021 | 675.86% | 坎托·菲茨杰拉德 | → 18 美元 | 启动覆盖范围开启 | → 超重 |
| 11/15/2019 | 417.24% | Maxim 集团 | → 12 美元 | 升级 | 持有 → 买入 |
| 2019 年 8 月 4 日 | 93.97% | 联盟全球合作伙伴 | → 4.5 美元 | 启动覆盖范围开启 | → 购买 |
| 2018 年 1 月 11 日 | 460.34% | 奥本海默 | → 13 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 07/20/2018 | 115.52% | Maxim 集团 | 13 美元 → 5 美元 | 维护 | 买 |
| 2018 年 2 月 4 日 | 374.14% | HC Wainwright & Co. | → 11 美元 | 启动覆盖范围开启 | → 购买 |
| 2018 年 3 月 19 日 | — | Maxim 集团 | 升级 | 持有 → 买入 |
SELLAS Life Sciences Gr Questions & Answers
SELLAS 生命科学 Gr 问题与解答
The latest price target for SELLAS Life Sciences Gr (NASDAQ: SLS) was reported by Cantor Fitzgerald on June 28, 2022. The analyst firm set a price target for $6.00 expecting SLS to rise to within 12 months (a possible 158.62% upside). 2 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2022年6月28日公布了SELLAS Life Sciences Gr（纳斯达克股票代码：SLS）的最新目标股价。该分析公司将目标股价定为6.00美元，预计SLS将在12个月内升至12个月内（可能上涨158.62％）。去年有两家分析公司公布了评级。
The latest analyst rating for SELLAS Life Sciences Gr (NASDAQ: SLS) was provided by Cantor Fitzgerald, and SELLAS Life Sciences Gr maintained their overweight rating.
SELLAS Life Sciences Gr（纳斯达克股票代码：SLS）的最新分析师评级由坎托·菲茨杰拉德提供，SELLAS Life Sciences Gr维持增持评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SELLAS Life Sciences Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SELLAS Life Sciences Gr was filed on June 28, 2022 so you should expect the next rating to be made available sometime around June 28, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与SELLAS Life Sciences Gr的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。SELLAS Life Sciences Gr的最新评级是在2022年6月28日公布的，因此您应该预计下一个评级将在2023年6月28日左右公布。
While ratings are subjective and will change, the latest SELLAS Life Sciences Gr (SLS) rating was a maintained with a price target of $10.00 to $6.00. The current price SELLAS Life Sciences Gr (SLS) is trading at is $2.32, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的SELLAS生命科学集团（SLS）评级维持不变，目标股价为10.00美元至6.00美元。SELLAS Life Sciences Gr（SLS）的当前交易价格为2.32美元，超出了分析师的预期区间。